Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)

v3.23.1
Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)
$ in Thousands
 3 Months Ended
Nov. 02, 2020
USD ($)
Feb. 25, 2019
USD ($)
agreement
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Agreements        
Long-term royalty and commercial payment receivables     $ 73,333 $ 63,683
Contingent consideration under RPAs and CPPAs     125 75
Bioasis | Royalty Purchase Agreement        
Agreements        
Percentage of option to purchase royalty right on future license agreements   1.00%    
Number of future license agreements under optional purchase right | agreement   2    
Obligation upon exercise of options per licensed product, second agreement   $ 300    
Obligation upon exercise of options per licensed product, third agreement   400    
Payments related to purchase of royalty rights and other commercial payment rights   300    
Long-term royalty and commercial payment receivables   400    
Contingent consideration under RPAs and CPPAs   75 75  
Changes in estimated fair value of contingent consideration     0  
Payments of contingent consideration     0  
Amount of allowance for credit losses     0 0
Bioasis | Royalty Purchase Agreement | Maximum        
Agreements        
Potential future cash payments   $ 200    
Bioasis | Second Royalty Purchase Agreement        
Agreements        
Payments related to purchase of royalty rights and other commercial payment rights $ 1,200      
Long-term royalty and commercial payment receivables $ 1,200      
Amount of allowance for credit losses     $ 0 $ 0